S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer

Phase 2

• Conditions: Colorectal Cancer
• Interventions: Drug: S-1, Leucovorin; Drug: leucovorin, 5-fluorouracil

• Registration Number: NCT01193452
• Lead Sponsor: Fudan University

Brief Summary

This phase II trial on the assumption that S-1 combined with Leucovorin may have better efficacy and safety than simplified 5-FU/LV infusion therapy in elderly patients with advanced colorectal cancer.

Detailed Description

This is a randomized phase Ⅱ study, in which S-1 is used in combination with leucovorin in elderly patients with advanced colorectal cancer as first-line treatment,comparing with sLV5FU2 therapy. The aim of this study is to determine the efficacy and safety of S-1/LV in elderly patients in the first-line setting. The other secondary endpoints are progression free survival,overall survival, and quality of life are also evaluated.

Study Timeline

• Status Verified: 2010-08
• Study Start: 2010-08
• Study First Submitted: 2010-08-31
• Study First Submitted QC: 2010-09-01
• Last Update Submitted: 2010-09-01
• Study First Posted: 2010-09-02
• Last Update Posted: 2010-09-02
• Primary Completion: 2011-02
• Study Completion: 2012-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Signed written informed consent
• Oral medication is acceptable
• Histologically confirmed colorectal carcinoma
• Male or female ≥ 65 years of age
• No prior chemotherapy,radiotherapy,target therapy and immunotherapy, except adjuvant chemotherapy with an interval of ≥ 180 days)
• Presence of at least one target lesion measurable by CT scan or MRI,within 15 days prior to trial
• The lab values within 2 weeks prior to trial should meet:

PLT ≥7.5*10^4/mm3 ANC≥2000/mm3 HB≥100g/L Total bilirubin < upper limit of normal level ALT/AST/ALP < 2.5 x UNL (<5 x UNL for patients with liver or bone metastasis) Serum creatinine < UNL

• Performance status (ECOG) 0~1
• Life expectation longer than 90 days

Exclusion Criteria

• Allergy to S-1,fluorouracil or leucovorin
• Any investigational agent(s) within 4 weeks prior to entry
• Previous or currently exposure to certain drugs which are proved to have influence on blood drug concentration
• Active infection
• Severe organ failures or diseases, including: intestinal obstruction, pulmonary fibrosis, uncontrolled diabetes mellitus,clinically relevant coronary disease, cardiovascular disorder or myocardial infarction,renal or liver failure, severe psychiatric illness,cerebral vascular disease and sever GI ulcer which need blood infusion.
• Uncontrolled hydrothorax,ascites and hydropericardium
• Multiple bone metastatic lesions
• Brain metastases
• Chronic diarrhea or digestive disfunction
• Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
• Strong willingness to receive surgery or highly potential to have intestinal obstruction which may need surgery intervention
• Other conditions that primary investigate or investigator consider to be unsuitable for the trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
S-1/LV	S-1, Leucovorin	S-1 combined with Leucovorin
sLV5FU2	leucovorin, 5-fluorouracil	5-FU/LV infusion

Primary Outcome Measures

Name	Time	Method
response rate	six weeks

Secondary Outcome Measures

Name	Time	Method
disease control rate	six weeks
overall survival	three months
quality of life	six weeks
time to treatment failure	six weeks
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	six weeks
progression free survival	six weeks

Trial Locations

Locations (1)

Jin Li'; 🇨🇳 Shanghai, Shanghai, China